Canada Latent Tuberculosis Infection Detection Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The Canadian LTBI detection market encompasses diagnostic tools and services that identify Mycobacterium tuberculosis infection before it becomes active disease. In 2025, the market is valued at approximately $45 million, with growth supported by federal and provincial tuberculosis control programs requiring screening of high-risk populations including recent immigrants, close contacts of active cases, and healthcare workers.

• •Primary test categories include Tuberculin Skin Tests and Interferon Gamma Release Assays used in clinical and public health settings
• •Market expansion is occurring across hospital laboratories, reference laboratories, and public health clinics

Canada's immigration policy brings approximately 300,000 to 400,000 new permanent residents annually, many originating from countries with TB incidence rates exceeding 100 per 100,000 population, creating sustained demand for LTBI screening. Federal immigration medical examination requirements mandate TB testing for applicants aged 11 and older from designated countries, providing a stable baseline market demand that complements domestic screening initiatives.

• •Immigration screening programs drive approximately 60% of LTBI testing volume across major urban centers including Toronto, Vancouver, and Montreal
• •Provincial public health guidelines increasingly recommend LTBI testing for high-risk populations, expanding testing beyond traditional immigration channels

The market divides into test type, end user, and geographic segments, with test type being the primary differentiator between traditional TST methods and modern IGRA technology. Urban centers with higher immigrant populations, particularly in Ontario, British Columbia, and Quebec, account for the largest share of LTBI testing volume, while western provinces show growing adoption of IGRA-based testing methods.

• •Ontario represents the largest regional market due to its concentration of immigration processing centers and diverse population demographics
• •Testing end users span hospital-based laboratories, private diagnostic laboratories, and public health authority facilities

What are the recent trends and outlook?

The market is expected to maintain its 5.8% annual growth trajectory through 2030 as provincial health authorities continue refining LTBI testing guidelines and expanding treatment programs to reduce active TB incidence. Technological improvements in point-of-care IGRA testing and digital health integration for tracking and follow-up care represent emerging opportunities that could accelerate market growth beyond current projections.

• •Shift toward IGRA testing continues as laboratory capacity expands, with IGRA capturing an increasing share of new test volume in urban centers
• •Government funding for tuberculosis elimination strategies aligns with WHO End TB targets, supporting sustained investment in detection infrastructure